The Pennington Biomedical Research Center is a health science-focused research center in Baton Rouge, Louisiana. It is part of the Louisiana State University System and conducts clinical, basic, and population science research.

During the past decade, Pennington Biomedical Research Center conducted 160 clinical trials. In the 10-year time frame, 160 clinical trials started and 50 clinical trials were completed, i.e. on average, 31.3% percent of trials that started reached the finish line to date. In the past 5 years, 70 clinical trials started and 35 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pennington Biomedical Research Center" #1 sponsor was "Pennington Biomedical Research Center" with 209 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Orexigen Therapeutics, Inc" with 5 trials sponsored, "Eisai Inc." with 4 trials sponsored and "Klein Buendel, Inc." with 4 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 51 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pennington Biomedical Research Center" #1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 22 trials as a collaborator, "Pennington Biomedical Research Center" with 16 trials as a collaborator, "National Institute on Aging (NIA)" with 10 trials as a collaborator, "National Institute on Minority Health and Health Disparities (NIMHD)" with 7 trials as a collaborator and "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 6 trials as a collaborator. Other collaborators include 201 different institutions and companies that were collaborators in the rest 148 trials.

According to Clinical.Site data, the most researched conditions in "Pennington Biomedical Research Center" are "Obesity" (56 trials), "Type 2 Diabetes" (15 trials), "Childhood Obesity" (14 trials), "Insulin Resistance" (11 trials) and "Overweight" (11 trials). Many other conditions were trialed in "Pennington Biomedical Research Center" in a lesser frequency.

Most popular intervention types in "Pennington Biomedical Research Center" are "Other" (74 trials), "Behavioral" (71 trials), "Drug" (63 trials), "Dietary Supplement" (29 trials) and "Device" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Pioglitazone" (4 trials), "Control" (3 trials), "Successful Aging" (3 trials) and "13C-MRS procedure/Acetate infusion" (2 trials). Other intervention names were less common.

The vast majority of trials in "Pennington Biomedical Research Center" are 227 trials for "All" genders, 41 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Pennington Biomedical Research Center". 3 are not yet recruiting, 32 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 205 completed trials in Pennington Biomedical Research Center, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Pennington Biomedical Research Center, 17 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 140 trials that are defined as “Not Applicable".

Pennington Biomedical Research Center has several departments that took part in Clinical trials: "Recruiting core Pennington" - 3 trials